Bridging pharmacotherapy and minimally invasive surgery in interstitial cystitis/bladder pain syndrome treatment

References

• Hanno PM, Erickson D, Moldwin R, et al. Diagnosis and treatment of interstitial cystitis/bladder pain syndrome: AUA guideline amendment. J Urol. 2015;193:1545–1553.
   PubMed Web of Science ®Google Scholar
• van de Merwe JP, Nordling J, Bouchelouche P, et al. Diagnostic criteria, classification, and nomenclature for painful bladder syndrome/interstitial cystitis: an ESSIC proposal. Eur Urol. 2008;53:60–67.
   PubMed Web of Science ®Google Scholar
• Dellis A, Papatsoris AG. Intravesical treatment of bladder pain syndrome/interstitial cystitis: from the conventional regimens to the novel botulinum toxin injections. Expert Opin Investig Drugs. 2014 Jun;23(6):751–757.
   PubMed Web of Science ®Google Scholar
• Ogawa T, Ishizuka O, Ueda T, et al. Current and emerging drugs for interstitial cystitis/bladder pain syndrome (IC/BPS). Expert Opin Emerg Drugs. 2015;20(4):555–570.
   PubMed Web of Science ®Google Scholar
• Engeler D, Baranowski AP, Borovicka J, et al. EAU guidelines on chronic pelvic pain. EAU Guidelines. Edn. presented at the EAU Annual Congress Copenhagen 2018. ISBN 978-94-92671-01-1.
   Google Scholar
• Ogawa Τ, Ishizuka Ο, Ueda Τ, et al. Pharmacological management of interstitial cystitis/bladder pain syndrome and the role cyclosporine and other immunomodulating drugs play. Expert Rev Clin Pharmacol. 2018;11(5):495–505.
   PubMed Web of Science ®Google Scholar
• Pazin C, de Souza Mitidieri AM, Silva AP, et al. Treatment of bladder pain syndrome and interstitial cystitis: a systematic review. Int Urogynecol J. 2016 May;27(5):697–708.
   PubMed Web of Science ®Google Scholar
• Parsons CL, Lilly JD, Stein P. Epithelial dysfunction in nonbacterial cystitis (interstitial cystitis). J Urol. 1991;145:732–735.
   PubMed Web of Science ®Google Scholar
• Chuang YC, Yoshimura N, Huang CC, et al. Intravesical botulinum toxin a administration produces analgesia against acetic acid induced bladder pain responses in rats. J Urol. 2004;172:1529–1532.
   PubMed Web of Science ®Google Scholar
• Theoharides C. Treatment approaches for painful bladder syndrome/interstitial cystitis. Drugs. 2007;67:215–235.
   PubMed Web of Science ®Google Scholar
• Meng E, Hsu YC, Chuang YC. Advances in intravesical therapy for bladder pain syndrome (BPS)/interstitial cystitis (IC). Low Urin Tract Symptoms. 2018 Jan;10(1):3–11.
   PubMed Web of Science ®Google Scholar
• Mulholland SG, Hanno P, Parsons CL, et al. Pentosan polysulfate sodium for therapy of interstitial cystitis: a double-blind placebo-controlled clinical study. Urology. 1990;35:552–558.
   PubMed Web of Science ®Google Scholar
• Hsu CC, Chuang YC, Chancellor MB. Intravesical drug delivery for dysfunctional bladder. Int J Urol. 2013;20:552–562.
   PubMed Web of Science ®Google Scholar
• Kuo YC, Kuo HC. Adverse events of intravesical onabotulinumtoxin A injection between patients with overactive bladder and interstitial cystitis-different mechanisms of action of botox on bladder dysfunction? Toxins (Basel). 2016 Mar 16;8(3):75–85.
   Web of Science ®Google Scholar
• Rahnama’i MS, Marcelissen T, Apostolidis A, et al. The efficacy of botulinum toxin A and sacral neuromodulation in the management of interstitial cystitis (IC)/bladder pain syndrome (BPS), what do we know? ICI-RS 2017 think thank, Bristol. Neurourol Urodyn. 2018 Jan 24 Epub ahead of print. DOI:10.1002/nau.23493.
   Web of Science ®Google Scholar
• Zhang W, Deng X, Liu C, et al. Intravesical treatment for interstitial cystitis/painful bladder syndrome: a network meta-analysis. Int Urogynecol J. 2017;28(4):515–525.
   PubMed Web of Science ®Google Scholar
• Cervigni M, Natale F, Nasta L, et al. Intravesical hyaluronic acid and chondroitin sulphate for bladder pain syndrome/interstitial cystitis: long-term treatment results. Int Urogynecol J. 2012;23(9):1187–1192.
   PubMed Web of Science ®Google Scholar
• Dellis A, Papatsoris A. Stem cell therapy for the treatment of Peyronie’s disease. Expert Opin Biol Ther. 2017;17(4):407–413.
   PubMed Web of Science ®Google Scholar
• Stenton GR, Mackenzie LF, Tam P, et al. Characterization of AQX-1125, a small-molecule SHIP1 activator: part 1. Effects on inflammatory cell activation and chemotaxis in vitro and pharmacokinetic characterization in vivo. Br J Pharmacol. 2013;168(6):1506–1518.
   PubMed Web of Science ®Google Scholar
• Aquinox Pharmaceuticals (Canada) Inc; Aquinox Pharmaceuticals (Canada) Inc. Efficacy and safety of AQX-1125 in IC/BPS (LEADERSHIP). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000 [cited 2018 Jul 13]. Available from: https//www.clinicaltrials.gov/ct2/show/study/NCT01882543 NLM Identifier: NCT0188254.
   Google Scholar
• Aquinox Pharmaceuticals (Canada) Inc. Efficacy and safety of 2 doses of AQX-1125 in subjects with interstitial cystitis/bladder pain syndrome (LEADERSHIP 301). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000 [cited 2018 Jul 13]. Available from: https://www.clinicaltrials.gov/ct2/show/study/NCT02858453 NLM Identifier: NCT02858453.
   Google Scholar
• Aquinox Announces Topline Results of Phase 3 LEADERSHIP 301 Clinical Trial in Interstitial Cystitis/Bladder Pain Syndrome. Aquinox [Internet]. 2018 Jun 27. [cited 2018 Jul 13]. Available from: http://investor.aqxpharma.com/news-releases/news-release-details/aquinox-announces-topline-results-phase-3-leadership-301.
   Google Scholar
• Freund-Michel V, Frossard N. The nerve growth factor and its receptors in airway inflammatory diseases. Pharmacol Ther. 2008;117(1):52–76.
   PubMed Web of Science ®Google Scholar
• Qu HC, Zhang W, Yan S, et al. Urinary nerve growth factor could be a biomarker for interstitial cystitis/painful bladder syndrome: a meta-analysis. PLoS One. 2014;9(9):e106321.
   PubMed Web of Science ®Google Scholar
• Seki S, Sasaki K, Fraser MO, et al. Immunoneutralization of nerve growth factor in lumbosacral spinal cord reduces bladder hyperreflexia in spinal cord injured rats. J Urol. 2002;168(5):2269–2274.
   PubMed Web of Science ®Google Scholar
• Kawamorita N, Yoshikawa S, Kashyap M, et al. Liposome based intravesical therapy targeting nerve growth factor ameliorates bladder hypersensitivity in rats with experimental colitis. J Urol. 2016;195(6):1920–1926.
   PubMed Web of Science ®Google Scholar
• Astellas Pharma Inc (Astellas Pharma Europe B.V.). A study to investigate efficacy, safety, pharmacodynamics and pharmacokinetics of ASP6294 in the treatment of female subjects with bladder pain syndrome/interstitial cystitis (SERENITY). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000 [cited 2018 Jul 13]. Available from: https://www.clinicaltrials.gov/ct2/show/study/NCT03282318 NLM Identifier: NCT03282318.
   Google Scholar
• Kim A, Shin DM, Choo MS. Stem cell therapy for interstitial cystitis/bladder pain syndrome. Curr Urol Rep. 2016;17:1.
   PubMed Web of Science ®Google Scholar
• Nickel JC, Irvine-Bird K, Jianbo L, et al. Phenotype-directed management of interstitial cystitis/bladder pain syndrome. Urology. 2014;84(1):175–179.
   PubMed Web of Science ®Google Scholar